Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;11(3):237-248.
doi: 10.2217/pmt-2020-0087. Epub 2021 Jan 18.

Oliceridine in the treatment of moderate to severe acute pain

Sarada S Eleswarpu  1 , Ashraf S Habib  1
Affiliations
Review

Oliceridine in the treatment of moderate to severe acute pain

Sarada S Eleswarpu et al. Pain Manag. 2021 May.

Abstract

Intravenous opioids are a mainstay for the management of moderate to severe acute pain. Opioid administration provides effective pain control at the cost of significant side effects. Commonly used opioids like morphine are nonselective μ-receptor agonists, which stimulate both the G-protein pathway, associated with the analgesic effect, and the β-arrestin pathway, associated with the side effects. Oliceridine is a G-protein selective ligand at the μ-receptor with less activation of the β-arrestin pathway. The drug has recently been US FDA approved. This review will focus on the efficacy and safety of intravenous oliceridine in the treatment of moderate to severe acute pain.

Keywords: G-protein biased ligand; G-protein selective ligand; TRV130; analgesia; analgesia-mu receptor; analgesia-opioid; g-protein ligand; oliceridine; parenteral opioid administration; side effects – opioids.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Substances

LinkOut - more resources